Drug research and manufacturing used to be more “one-size-fits-all” — with small pipelines, big batches, and global distribution. But cell and gene therapies, antibodies, and other advanced drugs are ...
Research shows that 77 percent of lab professionals now use public AI tools alongside their ELN. For many, this is not driven by policy decisions, but by necessity. Governed tools do not yet support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results